Source link : https://www.newshealth.biz/health-news/loncastuximab-rituximab-boosts-response-rates-in-r-r-follicular-lymphoma/
SAN DIEGO — The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a phase II trial. The single-arm study showed that 38 of 39 patients (97%) achieved a response at 12 weeks after treatment, with 26 (67%) achieving a complete […]
Author : News Health
Publish date : 2024-12-08 19:35:45
Copyright for syndicated content belongs to the linked Source.